---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-26-000095"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2026-10-29T20:12:11+00:00"
generated_at: "2026-10-29T20:13:07.337619+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q3 2026 net loss $24.2M; MAPKeeper 301 enrollment ahead of schedule, runway to 4Q 2028

## Summary
- Net loss attributable to common stockholders $24.2M, or $0.37/share, vs $15.0M ($0.38/share) in Q3 2025; R&D $20.7M vs $10.9M on higher clinical and personnel costs.
- Cash, cash equivalents and marketable securities $166.1M at Sept 30, 2026, down from $217.0M at Dec 31, 2025; runway now funded into 4Q 2028.
- Phase 2 1L pancreatic cancer atebimetinib + mGnP arm (N=55) follow-up extended because patients are living longer than projected; topline update now 1H 2027.
- Phase 3 MAPKeeper 301 enrollment ahead of schedule; target expanded from 510 to ~570 patients, with potential to accelerate current mid-2028 topline guidance.
- CEO Zeskind cited 17.3 months median overall survival reported at ASCO; first lung cancer patient in atebimetinib + cemiplimab Phase 2 dosed in 4Q 2026.

## SEC filing metadata
- accession: 0001790340-26-000095
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2026-10-29T20:12:11+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/0001790340-26-000095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-26-000095
- JSON: https://secwatch.observer/filing/0001790340-26-000095.json
- Plain text: https://secwatch.observer/filing/0001790340-26-000095.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.